Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India
NEW DELHI: Zydus Cadila has announced that it had received an approval from the Drugs Controller General of India (DCGI) to start the Phase 3 clinical trial in CoVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. The trials which will commence in December will be conducted on 250 patients across 20-25 centres in […]